Customer Testimonials

Learn how our global pharma and biotech customers trust Quotient Sciences' scientific expertise to deliver medicines to patients, faster.

From global pharma to emerging and established biotechs, we partner with companies to help get new medicines to patients faster, earning their trust, and sharing our expertise.

For over 30 years, Quotient Sciences has been a trusted partner for global pharma and biotech companies. We have helped our customers to refine and formulate an understanding of their incredible ideas, turning them into medicines of the future.

Read our customer testimonials and see how working with us had benefitted their companies, and how we gained their trust, time and understanding to accelerate their drug development programs.

Ensysce Biosciences

"I knew that traditional manufacture and release would make it impossible for us to clinically determine the correct nafamostat component of our drug product. Quotient Sciences explained to me how their Translational Pharmaceutics® platform could reduce our development timeline by defining a design space for ER release rate, ER/IR ratio, and nafamostat dose. Additionally, they could integrate real-time adaptive manufacturing with clinical testing to rapidly test the variables within the design space and optimize the nafamostat formulation."

Lynn Kirkpatrick, CEO of Ensysce Biosciences

Find out more

Endevica Bio

"Leveraging an integrated compounding pharmacy approach under the Translational Pharmaceutics® platform saved us over a million dollars because we didn’t need to invest in scaling up peptide synthesis. We were able to make just the right amount of drug product needed to achieve the results we were looking for... If someone were to ask if I would work with Quotient Sciences again, I’d give them two thumbs up all the way. As a start-up biotech, you cannot underestimate how difficult it is to find the right outsourcing partner. You must have a partner that is going to be able to help you through the hard stuff and help save you as much money as possible."

Russell Potterfield, CEO of Endevica Bio

Find out more


"We are very excited with the results of our first human study... we have been able to leverage Quotient Sciences’ Translational Pharmaceutics® platform to gain rapid access to the clinic, helping deliver these favourable results in a smooth and rapid fashion."

Dr Simon Yaxley, Director of Oxilio

Find out more

Crinetics Pharmaceuticals

"There is an art to the development of taste-masked oral products for pediatric indications. Quotient Sciences’ expertise in improving the taste, smell, and texture of oral formulations makes them the ideal partner for Crinetics’ pediatric clinical programs."

R. Scott Struthers, PhD, Founder & CEO of Crinetics

Find out more

Evecxia Therapeutics

"Our small biotech company worked with Quotient Sciences on developing a complex formulation and validating the different iterations of the formulation in PK clinical studies using the Translational Pharmaceutics® approach. The project was successful, and we were generally impressed by the skillsets, professionalism, and courtesy of Quotient Sciences' scientists and other subject experts. We have also chosen to work with Quotient Sciences on two subsequent projects."

Evecxia Therapeutics

Find out more

Corcept Therapeutics

"The Phase I study of CORT125134 was contracted out to Quotient Sciences, largely due to Quotient Sciences’ ability to integrate manufacturing and dosing on the same site. Dosing decisions could be made very rapidly as soon as data from the previous cohort was available - there was no need to define and manufacture all the doses up front - minimizing delay."

Hazel Hunt, Chief Scientific Officer at Corcept Therapeutics

Read case study

BioCryst Pharmaceuticals

"Quotient Sciences’ real-time manufacturing capabilities were a key factor in determining the speed at which this study could be concluded, offering the rare combination or GMP manufacturing and clinical administration on the same site, even for complex formulations and dosage forms. This allowed us to progress much faster."

Dr Phil Collis, Vice President of Development at BioCryst Pharmaceuticals

Read case study

Stealth BioTherapeutics

"My first response was this is too good to be true, they can’t do that. We’ve been looking for this type of solution for years – it can’t be done. However, we made a site visit and, within three days, accepted the proposal... We had clinical data within weeks... reducing the overall timeline by half, if not more.”

Deborah Gouveia, Vice President, Program & Alliance Management at Stealth BioTherapeutics

Read case study

MEI Pharma

"Quotient Sciences' has been a great partner to work with. Their project management was top-notch and costs remained within budget throughout our collaboration. Their scheduling and execution have been impeccable; the program has run like clockwork. As a client, you can’t really ask for more!"

Dr Ofir Moreno, Vice President of Research & Development at MEI Pharma

Read case study


"The combination of GMP manufacturing and clinical testing within one organization was, as far as we are aware, entirely unique... The understanding we have gained through working with Quotient Sciences in terms of both the formulation development and the manufacturing will be invaluable."

Dr David Hava, Chief Scientific Officer at Pulmatrix Inc.

Read case study

Amplyx Pharmaceuticals

"Due to the low density and poor flow characteristics of our drug substance, we experienced significant blend and content uniformity issues. By transferring our program to Quotient Sciences, the development team was able to quickly produce demo batches through multiple blending steps and roller compaction using the Gerteis Mini-Pactor. The increase in drug load from 25% to 40% was a significant improvement as we prepared for future Phase II/III trials and this ultimately benefits the patients by reducing the pill burden. We have successfully manufactured several GMP batches of tablets at various doses using a common blend. Quotient Sciences is an outstanding drug development partner with a no-nonsense approach, excellent communication, speed, and robust, easy-to-review documentation, from analytical methods to master batch records."

Sean Premeau, former Director, CMC at Amplyx Pharma (now part of Pfizer)

Drug Substance


"Quotient Sciences has worked with us on several pediatric projects and has been very effective in translating our product concepts into successful prototype formulations. We really appreciate the way they tune in to the broader, long-term objectives of our projects and are agile in delivering specific work packages that will contribute to the overall project’s success. They are skilled in applying their extensive technical expertise and understanding of the full pediatric pharma development process. Importantly, they are great at adapting to change and tenacious when it comes to problem-solving. They have proved to be an essential resource in developing our pediatric portfolio."

Clare Geesen, Operations Manager at Proveca

Clovis Oncology

"Quotient Sciences is an honest and straight-forward company with a very progressive attitude... What makes them unique is the way in which the pharmaceutical products are made on site and transferred, without leaving the building, to the clinical unit and a good, large and reliable pool of healthy volunteers."

Gillian C. Ivers-Read, Former Executive Vice President & Chief Regulatory Officer of Clovis Oncology

Read case study

Xspray Pharma

"Quotient Sciences offers the best balance of quality and timing versus cost of trials... Everything ran very smoothly. We had a very good project manager who was on top of things all the time, and there were no hitches... I would say that Quotient Sciences offers the best balance of quality and timing versus cost of trials."

Dr Andreas Konar, Senior Vice President of Business Development at XSpray

Read case study

Druggability Technologies

"Quotient Sciences has reduced our time-to-clinic and time-to-market. They understand the issues in drug development and have taken us from early stage to commercial in the most efficient way... Quotient Sciences have extensive knowledge beyond CDMO services, such as regulatory affairs, biopharmaceutics, and medical research. This means we can access skills that we don’t have internally."

Gábor Heltovics, Former CEO, Druggability Technologies

Read case study


"We were impressed by how efficient Quotient Sciences team was to help us progress one of our key projects to a successful first in human study."

Benoit Bestgen, Associate Director Product Development at Medicines for Malaria Venture (MMV)

Read our case studies

Triplet Therapeutics

"After taking everything into account - the manufacturing costs of a traditional CMO model, creating multiple lots of material that may never get used, etc. Quotient Sciences' Translational Pharmaceutics approach was a cost-effective option, especially when we took the additional cost of time saved into consideration."

Deborah Gouveia, Former SVP, Development Operations at Triplet Therapeutics

Synlogic, Inc

"The understanding we have gained through working with Quotient Sciences in terms of both the formulation development and the manufacturing will be invaluable."

Dr David Hava, Former Chief Scientific Officer at Synlogic, Inc.

An expert partner you can trust

When you partner with us, you can trust us to support your drug development program across the entire development pathway from candidate selection to commercial launch. Our scientific experts have over 30 years of experience, expanding drug development capabilities combined with our transparent methodologies and datasets, can deliver medicines to patients, faster. We have been proven time and time again to accelerate small molecule and peptide drug development with our integrated programs, streamlining the outsourcing paradigm for our customers.

Contact our experts

Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.